RayKnowChina Research Map
Shortlist

RecruitingGliomaPhase not stated

Registered title, quoted from ClinicalTrials.gov

Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study

An open trial on glioma, registered on ClinicalTrials.gov. Led by Renji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06002711, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Confirmed postoperative pathology of adult diffuse glioma (WHO Grade III-IV).

    Inclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06002711, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Retrospective Study:

  • Participants aged 18 to 70 years, of any gender.
  • Confirmed postoperative pathology of adult diffuse glioma (WHO Grade III-IV).
  • Standard MR contrast-enhanced imaging performed within 10 days before surgery.
  • No history of prior radiotherapy or chemotherapy before surgery.
  • Absence of concurrent significant comorbidities or other tumors.
  • Presence of molecular testing results (including IDH, MGMT, 1p19q, TERT, CDKN2A/B, BRAF).
  • Availability of comprehensive clinical and follow-up data.

Prospective Study:

  • Participants aged 18 to 70 years, of any gender.
  • Clinically suspected to have high-grade gliomas preoperatively, with final pathology confirming high-grade gliomas.
  • Stable vital signs and capable of cooperating for a 40-minute MR scan.
  • Absence of significant underlying medical conditions or history of other tumors.
  • Documentation of informed consent through a signed consent form.

Exclusion Criteria:

Retrospective Study:

  • MRI images with artifacts or presence of intratumoral hemorrhage.
  • Incomplete clinical data available.

Prospective Study:

  • Individuals with claustrophobia or other reasons unable to undergo MRI scans.
  • History of allergic reactions to MRI contrast agents.
  • Inappropriate for prolonged MRI scans due to other reasons.

Quoted from ClinicalTrials.gov, NCT06002711, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06002711, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06002711